Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10430 | 0.88 | BRD4 (0.52) | BRD4PTGER4MEN1KMT2ASCD | |
| SCHEMBL10429 | 0.88 | BRD4 (0.52) | BRD4PTGER4MEN1KMT2ASCD | |
| SCHEMBL11909477 | 0.86 | BRD4 (0.57) | BRD4PTGER4P2RX3P2RX2ACSS2 | |
| SCHEMBL11909475 | 0.86 | BRD4 (0.57) | BRD4PTGER4P2RX3P2RX2ACSS2 | |
| SCHEMBL10131 | 0.84 | BRD4 (0.55) | BRD4PTGER4 | |
| SCHEMBL22220768 | 0.84 | BRD4 (0.55) | BRD4PTGER4 | |
| SCHEMBL10132 | 0.84 | BRD4 (0.55) | BRD4PTGER4 | |
| SCHEMBL10327 | 0.83 | BRD4 (0.55) | BRD4PTGER4P2RX3P2RX2ACSS2 | |
| SCHEMBL10326 | 0.83 | BRD4 (0.55) | BRD4PTGER4P2RX3P2RX2ACSS2 | |
| SCHEMBL22220913 | 0.77 | BRD4 (0.51) | BRD4PTGER4P2RX3P2RX2ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | BRD4 277/4885PTGER4 2567/4885P2RX3 4563/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | BRD4 2526/4885PTGER4 1647/4885P2RX3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.